David L. Veenstra, PharmD, PhD
Articles by David L. Veenstra, PharmD, PhD

Do Targeted NGS Panels Include NSCLC Guideline-Recommended Biomarkers?
ByJade Reynolds, BS,Siyang Peng, MS,Elizabeth Brouwer, PhD,David L. Veenstra, PharmD, PhD,John L. Fox, MD, MHA This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted next-generation sequencing (NGS) panels.

Reimbursement for Genetic Variant Reinterpretation: Five Questions Payers Should Ask
ByDavid L. Veenstra, PharmD, PhD,John W. Rowe, MD,José A. Pagán, PhD,H. Shelton Brown, PhD,John E. Schneider, PhD,Avni Gupta, BDS, MPH,Sara M. Berger, MS, CGC,Wendy K. Chung, MD, PhD,Paul S. Appelbaum, MD Periodic reinterpretation of genetic sequencing results presents a challenge for developing transparent and systematic coverage and reimbursement policies.

Systematic Review of Comparative Effectiveness Data for Oncology Orphan Drugs
ByMindy M. Cheng, MS,Scott D. Ramsey, MD, PhD,Emily Beth Devine, PharmD, MBA, PhD,Louis P. Garrison, PhD,Brian W. Bresnahan, PhD,David L. Veenstra, PharmD, PhD This study critically assessed the published clinical and economic evidence supporting oncology orphan drugs marketed in the United States.

Toward Evidence-based Assessment for Coverage and Reimbursement of Laboratory-based Diagnostic and Genetic Tests
ByScott D. Ramsey, MD, PhD,David L. Veenstra, PharmD, PhD,Louis P. Garrison Jr, PhD,Rick Carlson, JD,Paul Billings, MD, PhD,Josh Carlson, MS,Sean D. Sullivan, PhD 
Genetic Testing and Pharmacogenomics: Issues for Determining the Impact to Healthcare Delivery and Costs
ByKathryn A. Phillips, PhD,David L. Veenstra, PharmD, PhD,Scott D. Ramsey, MD, PhD,Stephanie L. Van Bebber, MSc,Julie Sakowski, PhD 